The U.S. FDA approved Eli Lilly & Co. and Boehringer Ingelheim's Synjardy XR for adults with type 2 diabetes.
Synjardy XR is a combination of two drugs formulated to be taken once a day. The approval was based on clinical trials examining the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea in the treatment of adults with type 2 diabetes.
The drug is co-marketed by Eli Lilly and Boehringer Ingelheim. Synjardy XR is the eighth FDA-approved treatment from Eli Lilly and Boehringer's partnership.